Key facts
- Celvivo’s last known valuation is $25.7M (May 2025).
- It has raised $10.9M; the latest was Later Stage VC ($7.7M) in May 2025.
- Notable investors include Denmark's Export and Investment Fund, T&W Medical, EUREKA Network, Innovationsfonden.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Celvivo
- ·The full record, as it builds
Funding rounds
No funding rounds for Celvivo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celvivo
Developer of a 3D cell culture technology designed to grow cells so that they retain or recover their in vivo physiological attributes. The company's technology system creates an environment that promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, or other aggregates, enabling scientists from widely different areas to conduct research with cell cultures that mimic cells in the living organism.
- Sector
- Healthcare
- HQ
- Odense, Denmark
- Founded
- 2014
- Employees
- 30
- Website
- celvivo.com/
- Ownership
- Privately Held (backing)
Celvivo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celvivo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celvivo in its N-PORT filings yet. We sweep new filings monthly.